This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mo, Y.-Y. Articles by Beck, W. T. Search for Related Content PubMed PubMed Citation Articles by Mo, Y.-Y. Articles by Beck, W. T.

Overexpression of a Dominant-Negative Mutant Ubc9 Is Associated with Increased Sensitivity to Anticancer Drugs

Departments of ¹ Biopharmaceutical Sciences and ² Biochemistry and Molecular Genetics, and ³ the Cancer Center, University of Illinois at Chicago, Chicago, Illinois

Ubc9 is an E2-conjugating enzyme required for sumoylation and has been implicated in regulating several critical cellular pathways. We have shown previously that Ubc9 is important for sumoylation and nucleolar delocalization of topoisomerase (topo) I in response to topo I inhibitors such as topotecan. However, the role for Ubc9 in tumor drug responsiveness is not clear. In this study, we found that although MCF7 cells expressing a Ubc9 dominant-negative mutant (Ubc9-DN) display decreased activity of topo I, these cells are more sensitive to the topo I inhibitor topotecan and other anticancer agents such as VM-26 and cisplatin. In addition, we found that alteration of Ubc9 expression correlates with drug responsiveness in tumor cell lines. To understand possible mechanisms of Ubc9-associated drug responsiveness, we examined several proteins that have been shown to interact with Ubc9 and that may be involved in drug responsiveness. One such protein is Daxx, which is a Fas-associated protein that plays a role in Fas-mediated apoptosis by participating in a caspase-independent pathway through activation of apoptosis signal-regulating kinase 1 and c-Jun NH₂-terminal kinase. We found that cells expressing Ubc9-DN accumulate more cytoplasmic Daxx than the control cells. Because cytoplasmic Daxx is believed to participate in cellular apoptosis, we suggest that the interaction of Ubc9 with Daxx and subsequent alteration in the subcellular localization of Daxx may contribute to the increased sensitivity to anticancer drugs in the cells expressing Ubc9-DN. Finally, we found that overexpression of Daxx sensitizes cells to anticancer drugs possibly in part through alterations of the ratio of cytoplasmic and nuclear Daxx. Together, our results suggest a role for Ubc9 in tumor drug responsiveness.

This article has been cited by other articles:

				F. Wu, S. Chiocca, W. T. Beck, and Y.-Y. Mo Gam1-associated alterations of drug responsiveness through activation of apoptosis Mol. Cancer Ther., June 1, 2007; 6(6): 1823 - 1830. [Abstract] [Full Text] [PDF]

				R.-Y. Huang, D. Kowalski, H. Minderman, N. Gandhi, and E. S. Johnson Small Ubiquitin-Related Modifier Pathway Is a Major Determinant of Doxorubicin Cytotoxicity in Saccharomyces cerevisiae Cancer Res., January 15, 2007; 67(2): 765 - 772. [Abstract] [Full Text] [PDF]

				R. Muromoto, M. Ishida, K. Sugiyama, Y. Sekine, K. Oritani, K. Shimoda, and T. Matsuda Sumoylation of Daxx Regulates IFN-Induced Growth Suppression of B Lymphocytes and the Hormone Receptor-Mediated Transactivation J. Immunol., July 15, 2006; 177(2): 1160 - 1170. [Abstract] [Full Text] [PDF]

				H. R. Jacquiau, R. C. A. M. van Waardenburg, R. J. D. Reid, M. H. Woo, H. Guo, E. S. Johnson, and M.-A. Bjornsti Defects in SUMO (Small Ubiquitin-related Modifier) Conjugation and Deconjugation Alter Cell Sensitivity to DNA Topoisomerase I-induced DNA Damage J. Biol. Chem., June 24, 2005; 280(25): 23566 - 23575. [Abstract] [Full Text] [PDF]